The non-digestible polysaccharide Arabinoxylan may be an effective oral adjuvant to support vaccine efficacy, according to a new pilot study involving 231 elderly participants.
Producers of CPhI North America 2021 offer a glimpse at programming, including sessions on COVID-19 challenges, supply chain issues, and more key topics.
An industry study from the producer of CPhI North America shows the pandemic and other factors are contributing to a very dynamic pharmaceutical market.
The success of mRNA vaccine technology could be one of the new opportunities for US pharmaceutical manufacturing looking forward, with pandemic investments helping turbocharge the sector.
There is “some way to go” before UnitedHealth Group has the clarity to make a coverage decision on Biogen’s Alzheimer’s disease drug Aduhelm, according to the CEO of the healthcare company.
The drug, intended for adult patients with moderate-to-severe systemic lupus erythematosus, is the only new therapy approved for SLE in more than a decade.
Arcturus Therapeutics and its Vietnam partner Vinbiocare will take ARCT-154, a next-generation Arcturus vaccine targeting SARS-CoV-2 variants of concern, into a Phase 1/2/3 trial. The companies will also establish a vaccine manufacturing centre in Vietnam....
With Scancell taking its DNA-based COVID-19 vaccine tech into clinical trials this year, it is already focusing its attention on the tech’s potential to be used as a needle-free booster shot to address Variants of Concern.
The mRNA vaccine developed by Pfizer and BioNTech generates far higher levels of antibodies against the coronavirus than Sinovac’s inactivated virus prophylactic, according to a study.